Immunotherapy plus chemo with or without radiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding radiation therapy to a standard treatment (immunotherapy plus chemotherapy) can help people with advanced esophageal cancer that has spread to up to two organs. The goal is to see if the combination improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of esophageal cancer called squamous cell carcinoma that has spread to distant sites in no more than two organs.
- Your overall health is good enough to carry out daily activities (ECOG score 0 or 1).
- You have not had radiation to the chest before.
- You have not received surgery, chemotherapy, or other cancer treatment for this condition yet.
- You do not have active infections, serious heart or blood vessel problems in the last 6 months, or a history of severe allergies to chemotherapy drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding radiotherapy can help people with metastatic esophageal cancer that has already responded well to initial treatment with immunotherapy and chemotherapy. It may offer a way to improve outcomes for those whose cancer has not progressed after 2-4 cycles of first-line treatment.
This trial tests whether adding radiation therapy after initial chemoimmunotherapy improves outcomes for people with locally advanced esophageal cancer. It is designed for patients whose tumors are still responding or stable after the first treatment.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
This trial studies whether adding an anti-PD-1 immunotherapy (with chemotherapy) together with radiation can help people with advanced esophageal squamous cell cancer. It’s for cases where surgery or standard definitive chemoradiation can’t be done, or the cancer has spread to distant sites.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
Hear when a new Esophageal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.